



Wednesday, 19 April 2006

OBJ's DRUG DELIVERY TECHNOLOGY PROVEN IN HUMAN TRIAL

=====

OBJ Limited (ASX:OBJ) announced today that Curtin University, in Western Australia, had successfully completed a blinded placebo controlled human pilot study into the effects of the company's drug delivery technology on the speed of onset of a commercially available Tetracaine local anesthetic.

The study was designed to investigate the skin penetration enhancement of Dermaportation in vivo using loss of sensation due to local anaesthetic gel as a pharmacodynamic measure of skin penetration of the local anaesthetic drug (amethocaine/ tetracaine).

This is the first time the OBJ drug delivery patch has been demonstrated on live human skin.

The results of the pilot study are based on data from 5 healthy volunteers, each using two active and two passive Dermaportation patch applicators. During the study neither patients nor supervisors were aware of which patch applicators were active. Touch sensitivity was measured 15 minutes post administration using a computerized von Frey data capture system and supported by sharp/blunt determination tests.

The University concluded that the anaesthetic effects of a commercially available Tetracaine gel was increased by Dermaportation in all volunteer subjects, demonstrating that Dermaportation enhanced the penetration of the local anaesthetic. The study suggests that Dermaportation increases the speed of therapeutic onset of a leading drug, at lower dosages, without the need for reformulation or penetration enhancers.

Confirmation of efficacy in humans and clinical benefits with existing drugs at lower dosages are two key milestones for the company. The pilot study will be expanded to a full clinical trial later in the year at which time OBJ will seek to optimise the efficacy of its drug delivery technology by matching the delivery system to the molecular characteristics of the specific drug used.

For more information contact Jeffrey Edwards on +61 8 944 33011 or jedwards@obj.com.au

Background to the Announcement


OBJ Limited is a drug delivery company, specialising in electronic "drug patch" technologies that allow drugs, vaccines, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

The OBJ Dermaportation technology has been shown to manage and control the transdermal delivery of a broad range of drugs and therapeutic agents ranging from small difficult molecules such as Caffeine, through to large macro-globular proteins drugs such as vaccines.

OBJ's technology has been independently proven in both in-vitro and in-vivo studies and can manage a broader range of molecular sizes, structures and valencies than other active or passive drug delivery systems.

OBJ has been successful in managing the through-the-skin delivery of drugs used in the inflammation, pain, cancer and cosmetic fields.

OBJ's technology is low cost, and can be incorporated into reusable drug patches, (as illustrated) disposable single use drug patches and in a range of packaging systems for OTC and retail use.



Sustainable Benefits

Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins, vaccines, anti-bodies and anti-aging molecules has long been the desire of the pharmaceutical industry. It would provide economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Side effects could be reduced by localized delivery and programmed delivery rates. Needle stick injuries and needle disposable problems could be eliminated while the reduction in the level of skill required for application could significantly reduce total cost of many health programmes. These clear commercial benefits may only be achievable if the skin's natural barrier effect can be overcome.

OBJ is the first company to create a broad spectrum through-the-skin delivery system that is kind to the skin, completely reversible, yet can handle drugs range from the small difficult molecules up to the largest and most complex proteins and anti-bodies. OBJ manages an extensive IP portfolio and prosecutes patent applications throughout the world.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University. The high level of independence and international accreditation means that the results attributable to OBJ's proprietary technology can be published and presented at major medical and scientific conferences and forums.

OBJ Limited (ACN 056 482 636)

Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007

Phone: +61 8 9443 3011

Fax: +61 8 9443 3866

Email: jedwards@obj.com.au